痰瘀同治颗粒对冠心病痰瘀互结证中医证候和PPARγ表达的影响

Effects of Tanyu Tongzhi Granule on TCM syndrome and PPARγ of coronary heart disease

目的:观察痰瘀同治颗粒能否改善冠心病(胸痹)痰瘀互结证患者的中医证候;通过治疗前后对过氧化物酶体增殖物激活受体γ(PPARγ)变化情况的检测,探讨痰瘀同治颗粒防治冠心病的可能作用机制。方法:入选符合冠心病痰瘀互结证患者64例,包括对照组33例和治疗组31例。对照组采用常规治疗(阿司匹林、他汀类、血管紧张素转换酶抑制剂、β受体阻滞剂、钙离子拮抗剂、硝酸酯类、血运重建等),治疗组在常规治疗的基础上加用痰瘀同治颗粒,疗程为3个月。治疗前后对患者的中医证候进行记分,用Western Blot法检测单核细胞核蛋白PPARγ的表达。结果:与治疗前相比,治疗后两组患者各项中医证候记分明显降低(P<0.01),PPARγ蛋白浓度明显升高(P<0.01);治疗后,与对照组相比,治疗组患者的中医证候记分明显降低(P<0.05),PPARγ蛋白浓度明显升高(P<0.01)。结论:痰瘀同治颗粒能改善冠心病痰瘀互结证患者中医证候,提高单核细胞PPARγ蛋白表达水平。

Objective：To observe the effect of Tanyu Tongzhi Granule on TCM symptom of coronary heart disease （CHD） with syndrome of intermingled phlegm and blood stasis. The levels of peroxisome proliferator-activated receptor γ （PPARγ） before and after treatment were detected to explore the potential mechanism. Methods：64 Patients with CHD were divided into two groups,the control group （n=33） and the treatment group （n=31）,with and without Tanyu Tongzhi Granule treatment in addition to conventional therapy （such as aspirin,statins,angiotensin converting enzyme inhibitor,β-adrenergic receptor blockers,calcium channel antagonists,nitrates and so on） for 3 months. TCM symptom scores were recorded before and after treatment. The expression of PPARγ protein in peripheral lymphocytes was assessed by western blot. Results：At the end of 3 months,significant decrease in traditional Chinese medicine symptom scores （P0.01） and increase in the expression of PPARγ protein in human monocytes （P0.01） were observed in both groups than that of the baseline. Furthermore,the treatment group had better effect than the control group （P0.05 or P0.01）. Conclusion：In our study we discovered that the Tanyu Tongzhi Granule could improve the TCM symptom,and increase the expression of PPARγ protein in monocytes.